AMES, Iowa, March 12, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Oppenheimer 28th Annual Healthcare Conference, March 20, 2018 in New York City
- 8th Annual Cancer Immunotherapy Conference, hosted by William Blair & Company and MaidStone Life Sciences, April 5, 2018 in New York City
At the Oppenheimer 28th Annual Healthcare Conference, NewLink Genetics’ participation will consist of one-on-one meetings with investors.
At the 8th Annual Cancer Immunotherapy Conference, NewLink Genetics’ Chairman and Chief Executive Officer, Charles J. Link, Jr, MD, will give a brief presentation during the conference segment, “Tumor Microenvironment: Metabolites/Enzymes,” beginning at 11:10 AM ET.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com